CVS Health (CVS) Announces Expansion of Naloxone Accessibility
- Stocks close with gains, led by Dow as investors look for rate insight
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Robinhood (HOOD) rises after saying it plans to launch a credit card for US consumers
- Short sellers target Reddit shares as stock slips
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
CVS Health Expands Access to Opioid Overdose-Reversal Drug for CVS Pharmacy Patients in Five Additional States
September 29, 2016 8:31 AM EDTWOONSOCKET, R.I., Sept. 29, 2016 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced it has expanded access to the opioid overdose-reversal drug naloxone in Alabama, Alaska, Illinois, Missouri and West Virginia, allowing CVS Pharmacy patients to access the medication without an individual prescription. In total, CVS Pharmacy patients in 36 states now have increased access to the life-saving opioid overdose-reversal drug. CVS Health's naloxone program establishes a standing order with a physician in the state or utilizes pharmacists' prescriptive authority to permit CVS Pharmacists to dispense naloxone to patients without an individual prescription. ... More